Skip Navigation Links

Research & Development

At OCT we bring together the potential of natural molecules with the scientific rigour of pharmaceutical R&D practices to establish ourselves as a leader in cannabinoid pharmaceutical drug development.

Our aim is to tackle the pain pandemic, focusing on indications with currently untreatable severe pain,  including orphan indications, diseases which are rare and not successfully medicated. OCT evaluates different cannabinoid compounds for their medical potential, including proprietary derivative cannabinoid derivatives, natural phytocannabinoids and other drug compounds that interplay with the endocannabinoid system.

The company’s lead compound, OCT461201, is in development for primary indications of IBS-associated visceral pain and neuropathic pain conditions, including post herpetic neuralgia. OCT has also developed a library of proprietary cannabinoid derivative compounds that harness the therapeutic potential of cannabinoids, while improving on key characteristics through medicinal chemistry.

We are also planning to expand our pipeline by commissioning screening on an undisclosed receptor target using a diverse library of approximately 400,000 compounds. This has the potential to allow the Group to deliver a first-in-class drug for the treatment of neuralgias.

Although the Group is focused on developing drug products within the therapeutic area of pain, OCT may also screen compounds across additional therapeutic areas such as immunology, neurology and cancer.

Whether in-licensing promising compounds or outsourcing our assets to optimise application in different therapeutic areas, we are constantly looking to expand our pipeline. If you are interested in partnering on a cannabinoid-based project, please contact us.